NTRA's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 286 similar instances where the Aroon Indicator showed a similar pattern. In 244 of the 286 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 85%.
Following a +6.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day RSI Indicator for NTRA moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 22 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 56%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 65 cases where NTRA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 73 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 36 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (29.986) is normal, around the industry mean (65.876). NTRA's P/E Ratio (-280.681) is considerably lower than the industry average of (3.542). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
TMO saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 87 similar instances where the indicator turned positive. In 58 of the 87 cases, the stock moved higher in the following days. The odds of a move higher are at 67%.
Following a +2.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 192 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Aroon Indicator entered an Uptrend today. In 133 of 244 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 55%.
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 17 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 47%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 67 cases where TMO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 57%.
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 24 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 61%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 14 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 25 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.791) is normal, around the industry mean (65.876). P/E Ratio (36.682) is within average values for comparable stocks, (3.542). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 70 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
NTRA | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 8 | 70 | |
SMR RATING 1..100 | 94 | 60 | |
PRICE GROWTH RATING 1..100 | 35 | 14 | |
P/E GROWTH RATING 1..100 | 86 | 25 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (6) in the Biotechnology industry is somewhat better than the same rating for TMO (65) in the Medical Specialties industry. This means that NTRA’s stock grew somewhat faster than TMO’s over the last 12 months.
NTRA's Profit vs Risk Rating (8) in the Biotechnology industry is somewhat better than the same rating for TMO (70) in the Medical Specialties industry. This means that NTRA’s stock grew somewhat faster than TMO’s over the last 12 months.
TMO's SMR Rating (60) in the Medical Specialties industry is somewhat better than the same rating for NTRA (94) in the Biotechnology industry. This means that TMO’s stock grew somewhat faster than NTRA’s over the last 12 months.
TMO's Price Growth Rating (14) in the Medical Specialties industry is in the same range as NTRA (35) in the Biotechnology industry. This means that TMO’s stock grew similarly to NTRA’s over the last 12 months.
TMO's P/E Growth Rating (25) in the Medical Specialties industry is somewhat better than the same rating for NTRA (86) in the Biotechnology industry. This means that TMO’s stock grew somewhat faster than NTRA’s over the last 12 months.
| NTRA | TMO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 56% | 2 days ago 47% |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 57% |
| Momentum ODDS (%) | 2 days ago 75% | 2 days ago 67% |
| MACD ODDS (%) | 2 days ago 72% | 2 days ago 56% |
| TrendWeek ODDS (%) | 2 days ago 76% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 79% | 2 days ago 63% |
| Advances ODDS (%) | 6 days ago 80% | 6 days ago 62% |
| Declines ODDS (%) | 2 days ago 75% | 2 days ago 61% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 47% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 55% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NTRA’s FA Score shows that 2 FA rating(s) are green while TMO’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NTRA’s TA Score shows that 3 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s).
NTRA (@Medical Specialties) experienced а -6.42% price change this week, while TMO (@Medical Specialties) price change was -0.33% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.47%. For the same industry, the average monthly price growth was -4.50%, and the average quarterly price growth was +42.79%.
NTRA is expected to report earnings on Nov 05, 2026.
TMO is expected to report earnings on Feb 04, 2027.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ADPT. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ADPT could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | -8.54% | ||
| ADPT - NTRA | 55% Loosely correlated | -5.93% | ||
| NEO - NTRA | 55% Loosely correlated | -5.12% | ||
| GH - NTRA | 54% Loosely correlated | -4.51% | ||
| ISRG - NTRA | 53% Loosely correlated | +1.12% | ||
| TMO - NTRA | 48% Loosely correlated | -2.06% | ||
More | ||||
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | -2.06% | ||
| A - TMO | 74% Closely correlated | -1.65% | ||
| DHR - TMO | 72% Closely correlated | -1.83% | ||
| RVTY - TMO | 69% Closely correlated | -3.44% | ||
| IQV - TMO | 67% Closely correlated | -3.33% | ||
| BRKR - TMO | 67% Closely correlated | -2.42% | ||
More | ||||